Research
Hormonal
The oral formulation of semaglutide reduced AF incidence by 52%.
The oral formulation of semaglutide may be particularly effective in reducing AF risk.
StrongSupportsmedium confidence
The effect was more pronounced with the oral formulation, which reduced AF incidence by 52% (OR 0.48, 95% CI 0.24-0.95, p = 0.04).
Why this rating
Derived from a meta-analysis of multiple RCTs.
Source
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
Arturo Cesaro et al. · European Journal of Preventive Cardiology · 2025
DOI 10.1093/eurjpc/zwaf257
Meta-analysisCited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →